Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI2 | P48307 | 7/20 | 0.74 |
| ▸ | PPP5C | P53041 | 2/20 | 0.74 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.74 |
| ▸ | NPY4R | P50391 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12390209 | 1.00 | TFPI2 (0.74) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL19512780 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL2832350 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL19501013 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL12390164 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL26377801 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL9880148 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| Lb-100 SCHEMBL13311584 | 0.85 | TFPI2 (1.00) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL1572846 | 0.84 | TFPI2 (0.74) | TFPI2PPP5CPPP2CANPY4RHTT | |
| SCHEMBL12122108 | 0.83 | TFPI2 (0.65) | TFPI2PPP5CPPP2CANPY4RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9833450-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170259081-A1 | METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170209434-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H LEE MOFFITT CANCER CT & RES (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9526915-B2 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase | LIXTE BIOTECHNOLOGY, INC. | 2016-12-27 | — | — | US | disclosed |
| US-20160303115-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016134257-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTER BIOTECHNOLOGY, INC. (US) | 2016-08-25 | — | — | WO | disclosed |
| US-8329719-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120135522-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20110287537-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. | 2011-11-24 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-7998957-B2 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100029683-A1 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | TFPI2 4324/4885PPP5C 2709/4885PPP2CA 1893/4885 |
| US-20100029683-A1 | Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses | PSPH, PPP5C, BUB1B | TFPI2 2409/4885PPP5C 2/4885PPP2CA 73/4885 |
| US-20120270736-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | OAT, OGG1, OTC | TFPI2 4233/4885PPP5C 1913/4885PPP2CA 770/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | TFPI2 4843/4885PPP5C 2860/4885PPP2CA 2048/4885 |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPP3CA | TFPI2 912/4885PPP5C 7/4885PPP2CA 1/4885 |
| US-20170209434-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPM1A | TFPI2 1195/4885PPP5C 8/4885PPP2CA 1/4885 |
| US-20170369503-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-20160303115-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | HSD17B11, HSD17B1, CRH | TFPI2 4289/4885PPP5C 2219/4885PPP2CA 472/4885 |
| US-10023587-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885 |
| US-20170259081-A1 | METHODS FOR REGULATING CELL MITOSIS BY INHIBITING SERINE/THREONINE PHOSPHATASE | PPP5C, BUB1B, CDC25C | TFPI2 2737/4885PPP5C 1/4885PPP2CA 48/4885 |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | PPME1, PNKP, PPP6C | TFPI2 4590/4885PPP5C 9/4885PPP2CA 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.